JP6697403B2 - 炎症性腸疾患の処置のための方法及び医薬組成物 - Google Patents

炎症性腸疾患の処置のための方法及び医薬組成物 Download PDF

Info

Publication number
JP6697403B2
JP6697403B2 JP2016574360A JP2016574360A JP6697403B2 JP 6697403 B2 JP6697403 B2 JP 6697403B2 JP 2016574360 A JP2016574360 A JP 2016574360A JP 2016574360 A JP2016574360 A JP 2016574360A JP 6697403 B2 JP6697403 B2 JP 6697403B2
Authority
JP
Japan
Prior art keywords
colitis
seq
ox1r
antibody
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016574360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520554A5 (enExample
JP2017520554A (ja
Inventor
クーヴィノー，アラン
ヴォワザン，ティエリー
メサル，ナシマ
オジェ−ドゥニ，エリク
トレトン，クサヴィエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Université Paris Diderot - Paris 7
Original Assignee
Assistance Publique - Hôpitaux de Paris
Université Paris Diderot - Paris 7
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Université Paris Diderot - Paris 7 filed Critical Assistance Publique - Hôpitaux de Paris
Publication of JP2017520554A publication Critical patent/JP2017520554A/ja
Publication of JP2017520554A5 publication Critical patent/JP2017520554A5/ja
Application granted granted Critical
Publication of JP6697403B2 publication Critical patent/JP6697403B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016574360A 2014-06-24 2015-06-23 炎症性腸疾患の処置のための方法及び医薬組成物 Expired - Fee Related JP6697403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305990 2014-06-24
EP14305990.5 2014-06-24
PCT/EP2015/064028 WO2015197572A1 (en) 2014-06-24 2015-06-23 Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2017520554A JP2017520554A (ja) 2017-07-27
JP2017520554A5 JP2017520554A5 (enExample) 2018-08-02
JP6697403B2 true JP6697403B2 (ja) 2020-05-20

Family

ID=51062760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574360A Expired - Fee Related JP6697403B2 (ja) 2014-06-24 2015-06-23 炎症性腸疾患の処置のための方法及び医薬組成物

Country Status (5)

Country Link
US (1) US10172921B2 (enExample)
EP (1) EP3169348B1 (enExample)
JP (1) JP6697403B2 (enExample)
ES (1) ES2742179T3 (enExample)
WO (1) WO2015197572A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064302A1 (en) * 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CA3003283A1 (en) * 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
EP3454857A1 (en) * 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
EP4097119B1 (en) 2020-01-31 2025-05-07 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000787A2 (en) 1999-06-25 2001-01-04 Smithkline Beecham Corporation Methods of treatment using lig 72a and variants thereof
WO2004082715A1 (ja) * 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
KR20100057063A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도

Also Published As

Publication number Publication date
EP3169348B1 (en) 2019-07-31
WO2015197572A1 (en) 2015-12-30
ES2742179T3 (es) 2020-02-13
JP2017520554A (ja) 2017-07-27
US20170202925A1 (en) 2017-07-20
EP3169348A1 (en) 2017-05-24
US10172921B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
JP7196076B2 (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
US10172921B2 (en) Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
KR101699432B1 (ko) 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체
JP5513380B2 (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
CN114929278A (zh) 抗ccr8抗体及其用途
BR112021001201A2 (pt) anticorpo anti-tigit e uso do mesmo
JP7142200B2 (ja) ＭＡｄＣＡＭアンタゴニストの投与レジメン
BR112020006434A2 (pt) anticorpos anti-transtirretina
CN104602708A (zh) 痴呆症治疗药或预防药
CN110612120A (zh) 使用特异性于α4β7整联蛋白的抗体(维多珠单抗)治疗儿科病症的方法
JP2025519495A (ja) がんを治療するための抗ｐｄ－１活性薬剤、抗ｔｉｍ－３活性薬剤、および抗ｌａｇ－３活性薬剤の併用療法
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
CN107278207B (zh) 用于治疗转移性疾病的rankl特异性试剂
JP2016538286A (ja) 膵臓癌を処置するための方法及び医薬組成物
US11548942B2 (en) Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody
US20180339022A1 (en) Methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas
JP2008519028A (ja) Ｂ細胞悪性腫瘍の治療
CN104558175A (zh) 抗人vegf的重组嵌合抗体及其制备方法和用途
CN114026119A (zh) 结合pdgf-b和pdgf-d的抗原结合分子及其用途
US10329358B2 (en) Anti-human membrane-type ADAM28 antibody
JP2022174194A (ja) がんの処置のための抗ｔｎｆ関連アポトーシス誘発リガンド受容体２及び抗カドヘリン１７結合性二重特異的分子
JP2022130488A (ja) Ｐｄｇｆ－ｃｃの阻害のための方法および組成物
US20150140015A1 (en) Methods and pharmaceutical compositions for the treatment of pancreatic cancer
CN118271446B (zh) Rankl的抗体、抗原结合片段及其用途
KR20250036807A (ko) 신장 질환의 예방, 치료 또는 완화를 위한 융합 단백질

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200424

R150 Certificate of patent or registration of utility model

Ref document number: 6697403

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees